Skip to main content

Advertisement

Fig. 4 | Journal of Translational Medicine

Fig. 4

From: MYC copy gain, chromosomal instability and PI3K activation as potential markers of unfavourable outcome in trastuzumab-treated patients with metastatic breast cancer

Fig. 4

Effect of centromere profiles on the outcome of patients with metastatic breast cancer (mBC). In a, b, patients were distinguished in those who relapsed after adjuvant treatment (R-mBC), and those who presented with metastatic disease at first diagnosis (de novo mBC). In c, d, patients were grouped for centrally HER2-positive and HER2-negative disease. a, c Survival; b, d time to progression. 1chr increased CEN copies in 1 chromosome only; other normal CEN or increased copies for >1 CEN

Back to article page